The PERMEATE study
In this prospective, open-label trial, the investigators used ultra-widefield angiography and a novel quantification tool developed at the Cleveland Clinic to assess the longitudinal retinal vascular dynamics in patients with DME and RVO.
The key inclusion criteria were foveal-involving retinal edema secondary to DME or RVO and a best-corrected visual acuity (BCVA) of 20/25 or worse in the study eye. Patients were excluded who had been treated previously with intravitreal pharmacotherapy or laser photocoagulation in the study eye.
All eyes received intravitreal aflibercept monthly for the first 6 visits and then every other month for the next 6 visits. The patients were evaluated quarterly with ultra-widefield angiography to determine changes in ischemia, leakage, and microaneurysms.
Dr. Ehlers presented the interim data that included 26 patients who were divided evenly between the 2 retinal pathologies and who completed the 6-month evaluation. At baseline, the mean visual acuity was 20/80 and the mean central subfield thickness (CST) was 500 µm.
“As expected, the visual acuity outcomes were excellent, with a mean gain of about 17 letters of vision,” Dr. Ehlers reported. “About 38% of eyes achieved a 3-line or greater gain in vision.”